Table 8.
Antioxidant activities of 50–400 mg/kg/day of CVE in DOX-treated rat cardiac tissue.
| Groups | Antioxidant parameters | |||||
|---|---|---|---|---|---|---|
| GSH | GST | GPx | SOD | CAT | MDA | |
| I | 88.1 ± 5.3c− | 20.4 ± 0.1c− | 81.7 ± 4.9c− | 2.0 ± 0.2a− | 13.3 ± 1.7a− | 2.8 ± 0.1 |
| II | 62.8 ± 4.9f− | 21.4 ± 0.9f− | 69.4 ± 5.4 | 2.2 ± 0.1 | 11.3 ± 0.5 | 2.1 ± 0.3 |
| III | 51.2 ± 2.8c− | 20.8 ± 0.3f− | 51.5 ± 3.1f− | 3.3 ± 0.2 | 17.9 ± 1.1 | 3.5 ± 0.4 |
| IV | 77.6 ± 5.7 | 30.8 ± 0.7c+ | 81.4 ± 5.4 | 5.5 ± 1.1c+ | 35.6 ± 4.1c+ | 4.3 ± 0.3b+ |
| V | 45.6 ± 4.2c− | 21.5 ± 0.4f− | 50.3 ± 4.6f− | 4.0 ± 0.2a+ | 21.8 ± 1.6a+ | 3.9 ± 0.2a+ |
| VI | 65.7 ± 4.3c− | 22.3 ± 0.8f− | 64.6 ± 4.0d− | 2.8 ± 0.3 | 19.6 ± 0.7 | 6.4 ± 0.7c+ |
| VII | 112.6 ± 2.3c+ | 21.9 ± 0.3f− | 111.1 ± 2.3c+ | 5.3 ± 0.2c+ | 40.2 ± 1.7c+ | 4.5 ± 0.5b+ |
| VIII | 113.5 ± 2.2 | 23.6 ± 0.4 | 111.9 ± 2.2 | 2.5 ± 0.2 | 19.8 ± 1.5 | 2.4 ± 0.2 |
a−, c−Significant decreases at p < 0.05 and p < 0.0001, respectively, when compared to the untreated negative (normal) control value. c+A significant increase at p < 0.0001 when compared to the untreated negative (normal) control values. a+,b+Significant increases at p < 0.05 and p < 0.001, respectively, when compared to the untreated negative (normal) control values. d−,f−Significant decreases at p < 0.05 and p < 0.0001 when compared to the untreated positive (doxorubicin treated only) control values, respectively.